| 摘要 |
A new method of therapy using the subcutaneous mode of administration of formulations based upon harringtonines including their salts and tautomeric forms having the formula (I) where: R<1> is H, OH; Ome, O-(C1-C30)-alkyl, O-aryl-(C1-C30)-alkyl, O-aryl-(C1-C30)-alkenyl, O-(C3-C30)-cycloalkyl or null and R<2> is H or OH; or R<1>, R<2> form together O-, R<3> = R<4> Ome or R<3> and R<4> form together OCH2O- n is 0 to 8, R<5> is H, OH, Ome, 0-(C1-C30)-alkyl, O-aryl-(C1-C30)-alkyl, O-(C2-C30)-alkenyl, O-(C3-C30)-cycloalkyl or O-aryl, Z = O, S, or NH, and Formula (II) or Z-R<8> is NR<12>R<13> , R<12> and R<13> representing respectively R<9> and R<10>, R<9>, R<10>, R<11> are independently H, C1-C30 alkyl, C3-C30 cycloalkyl, aryl, aryl-(C1-C30)-alkyl, C2-C30 alkenyl, C2-C30 alkynyl, C1-C30 trihalogenoalkyl, C1-C30 alkylamino-(C1-C30)alkyl, C1-C30 dialkylamino(C1-C30)-alkyl, or amino-(C1-C30)-alkyl, or Formula (III) where R<14>, R<15>, R<16> are independently H, halogen, C1-C30 alkyl, C3-C30 cycloalkyl, aryl, aryl-(C1-C30)-alkyl, C2-C30 alkenyl or C2-C30 alkynyl, C1-C30trihalogenoalkyl, m is 0 to 4, each of these groups including or not heteroatom(s) or their combination with another antitumor agent or a mixture of antitumor agents useful for the treatment of a disease in humans or animals, particularly cancers, leukemias, lymphomas, parasite diseases or chemotherapeutic resistance to other agents, in using a formulation specifically adapted for subcutaneous administration.
|
